Myriad Genetics Sells Prenatal Unit to Labcorp for $210M, Raises 2026 Outlook to $785M Midpoint

Event Analysis

Myriad Genetics (NASDAQ: MYGN) has entered a definitive agreement to divest its Prenatal Health testing business — including the Prequel, Foresight, SneakPeek, and FirstGene brands — to Labcorp (NYSE: LH) for $210 million in cash plus the value of related inventory at closing. The transaction, announced in October 2026, is expected to close by early 2027, subject to regulatory approvals. Following the deal, Myriad raised its 2026 revenue guidance to $780M–$790M (midpoint $785M), with the prenatal segment still contributing roughly $160M to 2026 figures while Myriad retains ownership through year-end.

The strategic logic is a classic portfolio rationalization: Myriad sheds a lower-margin, volume-sensitive prenatal business to concentrate on its Cancer Care Continuum and Mental Health franchises. Management projects the divestiture will improve post-closing revenue growth by more than one percentage point and lift gross margin by more than five percentage points — a meaningful structural upgrade that the headline guidance revision alone understates. The deal was struck at approximately 1.3x trailing-12-month revenue for the prenatal assets, a multiple that sets a market benchmark for how investors may price comparable diagnostics units.

Labcorp's perspective is equally strategic. As reported by Market Chameleon, management guided for roughly $160M in first-year revenue from the acquired assets and slight adjusted-earnings accretion, with margins expected to converge to diagnostics-segment averages by year two. This signals Labcorp views prenatal testing as a scalable, bolt-on fit rather than a transformative bet, limiting execution risk. What distinguishes this deal from generic lab-services M&A is its dual effect: it simultaneously re-profiles Myriad toward faster-growing oncology diagnostics while giving Labcorp incremental prenatal scale in a consolidating market.

The 2027 revenue cliff deserves attention. Once Prenatal Health exits the Myriad base, reported revenue resets lower — the $620M–$630M core (Cancer Care + Mental Health) becomes the new baseline. Investors will need to anchor valuation to that post-divestiture run-rate rather than the 2026 consolidated figure.

What This Means for Traders

For MYGN, the near-term directional bias is cautiously constructive. The cash infusion strengthens the balance sheet, the margin upgrade thesis is credible, and oncology diagnostics tend to command premium multiples relative to prenatal screening. However, the 2027 revenue reset creates a valuation discontinuity that may weigh on price action if the market front-runs the post-closing earnings base. Traders focused on acquisition-driven stock moves should watch for a re-rating toward an oncology-pure-play comp set — which could meaningfully shift the fair value range. Volatility is likely elevated around closing confirmation and any 2027 guidance issuance.

For Labcorp (LH), the deal is incrementally positive but not a material re-rating catalyst given the relatively modest $160M revenue contribution versus LH's scale. The more instructive signal is sector-wide: the 1.3x revenue multiple for prenatal diagnostic assets may prompt a broader reassessment of similar business lines at other molecular diagnostics companies. Traders monitoring the diagnostics and healthcare sector should watch for sympathy moves in peers. Cross-market implications for indices are minimal — this is a purely idiosyncratic corporate event with limited spillover to the Russell 2000 beyond MYGN's weighting.

Note that MYGN stock CFDs on CoinUnited.io follow standard stock CFD trading sessions and are not available 24/7, so position entry around closing announcements or earnings updates should account for session timing.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices and commodities from one crypto-funded account. Leverage up to 2000x on selected products, subject to eligibility; fees are tiered by 30-day volume.